Safety and Tolerability of Sacubitril/Valsartan in Heart Failure Patient With Reduced Ejection Fraction
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 121 participants.
Also called NCT05387967
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 121 participants
- Registry
-
NCT05387967
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Pakistan
- Registry status
- Completed
Technical summary
Registry record NCT05387967. Allocation not applicable; no masking; primary purpose treatment. Start 2021-01-01 (actual); primary completion 2021-06-30 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Safety and Tolerability of Sacubitril/Valsartan in Heart Failure Patient With Reduced Ejection Fraction
- Condition
- Heart Failure, Systolic
- Intervention (Drug)
- Sacubitril/valsartan
- Lead sponsor
- National Institute of Cardiovascular Diseases, Pakistan
Record details
- Record id
cardio:ct-nct05387967- Content hash
989f9a0665f5a3924d14a13d21b55978dba5f86ff4264b8a19bd8882bc57a0da